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The global human immunodeficiency virus (HIV)epidemic is characterized by significant genetic diversity in
circulating viruses. We have recently characterized a group of viruses that form a distinct sub-subtype within
the subtype A radiation, which we have designated HIV type 1 (HIV-1) sub-subtype A, circulating in West
Africa. A prospective study of a cohort of female sex workers (FSW) in Dakar, Senegal over an 18-year period
indicated that an A3-specific sequence in the C2-V3 region of the env gene was found in 46 HIV-1-infected
women. HIV-1 sub-subtype A3 appeared in the FSW population as early as 1988 and continued to be trans-
mitted as of 2001. We also found that HIV-1 A3 is not confined to the FSW cohort in Senegal but is also
circulating in the general population in Dakar. Furthermore, analyses of viral sequences from a few other West
and Central African countries also demonstrated evidence of HIV-1 A3 sequence in isolates from HIV-1-
infected people in Ivory Coast, Nigeria, Niger, Guinea Bissau, Benin, and Equatorial Guinea. Overall, because
of the evidence of sub-subtype A3 in the general population in Senegal, as well as in a few neighboring West
and Central African countries, along with the increasing incidence of infection with A3-containing viruses in
the Dakar high-risk FSW population, we feel that HIV-1 sub-subtype A3 viruses are important to distinguish
and monitor.
Molecular surveillance has revealed significant heterogene-
ity in the prevalence and geographic distribution of various
subtypes worldwide (5, 35, 36). For example, subtype B viruses
account for an estimated 12.3% of cases globally, but infections
with this subtype are primarily seen in the Americas, Western
Europe, and Australia (35). Conversely, subtype C viruses
were estimated to have caused 47% of the worldwide infec-
tions, with the highest incidence in southern African countries,
Ethiopia, and India (35). As with the nonrecombinant sub-
types, circulating recombinant forms (CRFs) also show
founder effects and uneven geographic distributions. For ex-
ample, CRF01_AE appears to be the cause of a high propor-
tion of infections in Southeast Asia and seems to be largely
confined to that area of the world with relatively little spread
into other populations (35). In contrast, CRF02_AG contrib-
utes to a major number of new infections in West Africa and
appears to be associated with rapidly spreading epidemics in
West African countries (3, 6, 7, 28, 31, 35, 37). The underlying
causes of the varied geographic distributions are most likely
founder effects with other contributing factors, such as human
population movements, unregulated commercial sex work, and
intravenous drug use.
Over the course of an 18-year prospective study monitoring
a cohort of female sex workers (FSWs) in Dakar, Senegal, we
found that the most prevalent circulating strain in the cohort is
CRF02_AG, as seen in other parts of West Africa (2, 6, 7, 28,
31, 35, 37). However, recent work conducted in our lab re-
vealed that a unique group of viruses within the human immu-
nodeficiency virus type 1 (HIV-1) subtype A radiation is also
present in the FSW study population (40, 42). Through phy-
logenetic analyses, we have shown that this subcluster of vi-
ruses can be classified as HIV-1 sub-subtype A3 (30). The goal
of the current investigation was to understand the distribution
and dynamics of HIV-1 A3 in the Dakar FSW cohort. We
examined the molecular epidemiology of sub-subtype A3 in
Senegal, as well as other West and Central African countries.
This investigation revealed that there were 46 women in the
cohort with the A3 sequence in the C2-V3 region of the env
gene. Furthermore, analyses of GenBank-submitted sequences
from other West African countries revealed evidence of A3
sequence in isolates from Ivory Coast, Nigeria, Niger, Guinea
Bissau, Benin, and Equatorial Guinea. Our findings also indi-
cate that sub-subtype A3 viruses entered the high-risk popu-
lation of Dakar FSWs as early as 1988, with continued trans-
mission.
MATERIALS AND METHODS
Study population and sample collection. Since 1985, we have conducted a
prospective study of registered FSWs in Dakar, Senegal; blood samples and
questionnaire data were collected after obtaining informed consent. The specific
details of the study recruitment procedures and methods have been described
elsewhere (21, 22). Serostatus was determined by immunoblot on whole virus
lysates and recombinant envelope peptides and by diagnostic HIV-1 and/or
HIV-2 PCR. The time of infection for women who converted to HIV-positive
serostatus while in the study was estimated as the midpoint between their last
seronegative and first seropositive samples. HIV-1-positive person-years of ob-
servation was calculated as described previously (22).
DNA amplification and sequencing. Proviral DNA was extracted from periph-
eral blood mononuclear cells by using a kit from Qiagen, Inc. (Chatsworth,
Calif.). The C2-V3 env region (350 bp) for all of our samples was amplified by
nested PCR with primers and reaction conditions that have been described
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FIG. 1. (a) Distribution of HIV-1 CRF02_AG and A3 infections by year of seroconversion among Senegalese FSWs that were seroincident in
the cohort. For each subject, the first bleed date, the time of seroconversion to HIV-1-positive status, and the last bleed date are plotted. The
position of the triangles for each subject corresponds to the time of seroconversion. The shading and sizes of the triangles correspond to the
HIV-1A sub-subtype or CRF with which the individual was infected: , first bleed date; ‹, seroconversion date for HIV-1 A3-infected subjects;
, seroconversion date for HIV-1 CRF02_AG-infected subjects; , last bleed date. (b) Annual incidence of HIV-1A env sub-subtypes in the
Senegalese FSW cohort. Incidence rate per 100 person-years of observation (PYO) of each of the subtype A env viruses is plotted in 3-year
intervals. The y axis indicates the incidence rate per 100 person-years of observation, and the x axis indicates the time period to which the values
correspond. Shading of rectangles corresponds to HIV-1 sub-subtype or CRF with which the individual was infected: ■, A3; , CRF02_AG.
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previously (22, 41, 48). The PCR products were purified and directly sequenced
by using the second-round primers. In cases in which poor data or highly heter-
ogeneous sequences were obtained from direct sequencing, purified products
were cloned into the pCR2.1 vector (T/A Cloning; Invitrogen, San Diego, Calif.).
Sequences for both strands of DNA were determined by dye terminator cycle
sequencing with Taq polymerase (Perkin-Elmer Applied Biosystems Division,
Foster City, Calif.) and an automatic sequencer (ABI 373; Perkin-Elmer Applied
Biosystems Division).
Sequence analysis and statistical methods. Multiple alignments of all of
the consensus sequences to reference sequences from all of the major sub-
types and sub-subtypes (A1, A2, A3, B, C, D, F1, F2, G, H, J, and K), as well as
CRF02_AG, were performed by using the ClustalX package (45). Manual ad-
justments, when necessary, were made by using the MacClade version 4.05
program (Sinauer Associates, Inc., Sunderland, Mass.). For reference A3 se-
quences, we used AY521629 (DDI579), AY521630 (DDJ360), and AY521631
(DDJ369) (30). Phylogenetic analyses were performed, using the SEQBOOT,
DNADIST, NEIGHBOR, and CONSENSE programs in the Phylip version 3.6
package (11). Neighbor-joining trees were generated by using the F84 model of
substitution and a transition/transversion ratio of 1.42 (24). Alignments were gap
stripped prior to analyses. Trees were visualized by using NJPlot (38).
In order to determine whether there was evidence of A3 sequence in any other
regions of the world, a BLAST (http://www.ncbi.nlm.gov/BLAST) search was
conducted with reference A3 sequences. Once a subset of sequences was ob-
tained, more detailed phylogenetic analyses were performed. Neighbor-joining
trees, using an F84 model of evolution and a transition/transversion ratio of 1.42
were generated. For these trees, all major subtype, sub-subtype, and CRF02_AG
reference sequences were included in the analyses.
Sequence information. The sequences have been deposited into the GenBank
database under accession numbers AY646116 to AY646151.
RESULTS
From 1987 through 2001, 3,681 women were enrolled in the
Dakar FSW cohort, 491 (13.3%) of whom were or became
infected with HIV-1. Of the HIV-1-infected in the cohort, 175
(35.6%) were seroincident with HIV-1 only and 253 (51.5%)
were seroprevalent with HIV-1 only; the remaining subjects
were dually infected with HIV-1 and HIV-2.
Epidemiology of HIV-1 A3 in Senegalese FSW cohort. Of the
HIV-1-infected women, including those that were dually infect-
ed, we identified 301 (61%) women whose HIV-1 sequences
were subtype A in the env. Of the 301 women, 46 (21%) had
sequences that clustered distinctly from CRF02_AG as well as
HIV-1 sub-subtypes A1 and A2, as HIV-1 sub-subtype A3
viruses. Overall, 9.4% of the HIV-1 infections in the Dakar
FSW were attributed to HIV-1 A3. Of the 46 women whose
viral sequences clustered as sub-subtype A3 (30), 26 (56.5%)
were seroincident with HIV-1 only, 2 (4.3%) were seroincident
and dually infected (Table 1), 14 (30.4%) were seroprevalent
and infected with HIV-1 only, and the remaining 4 (8.7%)
were seroprevalent and dually infected (Table 2).
A time-lapse graph was generated to examine the appear-
ance and prevalence of A3 in the cohort (Fig. 1a). This graph
included all of the seroincident subjects in the Senegalese FSW
cohort who had been identified as infected with either A3 or
CRF02_AG. For each subject, we plotted first bleed date,
seroconversion date, and last bleed date. The data indicated
that the first evidence of HIV-1 seroconversion with A3 oc-
curred in 1991. However, when examining study entry dates for
seroprevalent subjects (Table 2), we found evidence of A3
infection as early as 1988. Overall, the annual incidence of A3
has steadily increased from 0% in the time period of 1987
through 1989 to an average of 0.67% in the time period of 1999
through 2001 in this FSW population (Fig. 1b).
Kaplan-Meier analyses were conducted to determine wheth-
er there was any difference between women in our cohort in-
fected with A3 and those infected with CRF02_AG in terms of
progression to AIDS. We did not find a statistically significant
difference between the two groups (data not shown). Interest-
ingly, nonparametric univariate analyses indicated that women
infected with A3 had a longer time to HIV-1 infection from the
date at which they self-reported starting commercial sex work
TABLE 1. Seroincident subjects in Senegalese FSW cohort







DDA360 HIV-1 only 1988 1991
DDA738 HIV-1 only 1988 1991
DDI578 HIV-1 only 1985 1992
DDA502 HIV-1 only 1986 1992
DDB231 HIV-1 only 1990 1993
DDI579 HIV-1 only 1987 1994
DDB266 HIV-1 only 1995 1995
DDB645 HIV-1 only 1988 1997
DDI509 HIV-1 only 1989 1997
DDF709 HIV-1 only 1990 1997
DDB754 HIV-1 only 1993 1997
DDI569 HIV-1 only 1990 1998
DDI582 HIV-1 only 1994 1998
DDI568 HIV-1 only 1988 1999
DDI570 HIV-1 only 1990 1999
DDI989 HIV-1 only 1996 1999
DDI601 HIV-1 only 1998 1999
DDJ351 HIV-1 only 1986 2000
DDJ321 HIV-1 only 1988 2000
DDJ201 HIV-1 only 1997 2000
DDJ338 HIV-1 only 1985 2001
DDJ452 HIV-1 only 1987 2001
DDI998 HIV-1 only 1991 2001
DDJ200 HIV-1 only 1995 2001
DDI963 HIV-1 only 2000 2001
DDI983 HIV-1 only 2001 2001
DDA482 HIV-1 and HIV-2 1985 1992
DDB252 HIV-1 and HIV-2 1993 1994
TABLE 2. Seroprevalent subjects in Senegalese FSW cohort
with A3 sequence in the C2-V3 region (env)
Subject Serohistory Yr enrolledin cohort
DD170 HIV-1 only 1988
DD737 HIV-1 only 1993
DDB107 HIV-1 only 1993
DDA399 HIV-1 only 1993
DDA467 HIV-1 only 1993
DDC571 HIV-1 only 1995
DDH188 HIV-1 only 1995
DDH189 HIV-1 only 1996
DDH394 HIV-1 only 1998
DDI944 HIV-1 only 1998
DDJ371 HIV-1 only 1998
DDJ426 HIV-1 only 2000
DDJ330 HIV-1 only 2000
DDI979 HIV-1 only 2001
DDB85 HIV-1 and HIV-2 1989
DD935 HIV-1 and HIV-2 1989
DDB501 HIV-1 and HIV-2 1992
DDE303 HIV-1 and HIV-2 1997
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FIG. 2. Evaluation of sequences from studies conducted on other cohorts in Senegal, as well as those in other countries in West Africa. Evidence of sequences clustering
with A3 viruses identified in our Senegalese FSW cohort was found in another Senegalese cohort (46), as well as in the Ivory Coast (9), Nigeria (29, 37), Niger (26),
Guinea-Bissau (3), Benin (14), and Equatorial Guinea (34). Phylogenetic trees including GenBank-submitted sequences from each of these respective locations are shown.
All trees were generated by using an F84 model of evolution, a transition/transversion ratio of 1.42 and references from all published subtypes and sub-subtypes (A1, A2, B-D,
F1, F2, G, H, J, and K), as well CRF02_AG. For reference A3 sequences, AY521629 (DDI579), AY521630 (DDJ360), and AY521631 (DDJ369) were used. Only bootstrap
values of80 are indicated at the major branch points. The A3 sequences are in boldface. Arrows link phylogenetic trees with the appropriate sequences to their corresponding
geographic sources.
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than did those women infected with CRF02_AG (12.9  9.4
versus 7.4  6.2, respectively; P  0.02). We also found that,
on average, women infected with A3 were older at time of
seroconversion than those infected with CRF02_AG (39.7 ver-
sus 35.4, respectively; P  0.04). There was no statistically
significant difference between those infected with A3 and those
infected with CRF02_AG with respect to age at which sex work
began (27.4 versus 27.9, respectively; P  0.67). There were
no statistically significant differences between the two groups
with regard to nationality, religion, ethnicity, or level of edu-
cation.
Evidence of HIV-1 A3 in other West and Central African
populations. In order to determine whether A3 was specific to
the high-risk population in Dakar, we obtained GenBank-sub-
mitted sequences from a study conducted by Toure-Kane et al.
in Senegal (46) that looked at sequences from HIV-1-infected
people attending a hospital in Dakar, Senegal. The sequences,
which had previously been designated “A” (A prime) by
Toure-Kane et al. (AJ272646, AJ272648, AJ272656, AJ272659,
AJ272669, and AJ272680) (46), clustered with our reference
A3 sequences. In addition, we wanted to examine whether
there was evidence of spread of A3 to other neighboring Af-
rican countries (3, 4, 9, 14, 26 27, 33, 34, 43, 44). We first
conducted a BLAST search to identify a subset of GenBank
submitted sequences, which might have originally been classi-
fied as subtype A, that would potentially cluster with sub-
subtype A3 reference sequences. Phylogenetic analyses indi-
cated that a few of the previously characterized sequences
from Ivory Coast (AF000450, AF000453, AF000456,
AF000466, and AF000475) (9), Equatorial Guinea
(AF530014) (34), Niger (AJ429851, AJ429856, AJ429866,
AJ429869, and AJ429875) (26), Guinea-Bissau (AF178170,
AF178172, AF178184, and AF178195) (3), Nigeria (AF069932,
AJ389774, AY653735, and AY653736) (29, 37), and Benin
(U61862 and U61866) (14) clustered with sub-subtype A3 vi-
ruses identified in the Dakar FSW cohort (Fig. 2). Finally, we
also found evidence of A3 in West Brittany, France
(AF461904) (47). Although this sequence had previously been
characterized as sub-subtype A1, we found that it clustered
with our A3 reference sequences, but with a relatively low
bootstrap value (data not shown).
DISCUSSION
We have determined that 9.4% of the HIV-1-infected wom-
en in the Senegalese FSW cohort are infected sub-subtype A3.
We have shown that HIV-1 A3 has been circulating in the
Dakar FSW study population from as early as 1988 and that
the incidence of HIV-1 infections due to A3 in this cohort is
increasing. Our analyses also indicate that there is evidence of
HIV-1 A3 in other populations, including those in some neigh-
boring West and Central African countries.
Although we are uncertain as to when A3 was actually in-
troduced into the cohort, the time-lapse graph indicates that
the A3 sub-subtype has been newly infecting our population
since 1991. Furthermore, our records indicate that a seropreva-
lent A3-infected subject first entered the cohort in 1988, which
dates sub-subtype A3 to the early part of the HIV-1 epidemic
in Senegal. Because this first case of A3 in our population was
seroprevalent, her date of seroconversion could have been
much earlier, so it is possible that A3 has been present in the
population for even longer. Regarding the origin of sub-sub-
type A3, it is also interesting that we have identified sequences
from a few other West and Central African countries that
cluster with A3 viruses found in the Senegalese FSW cohort.
This finding was not surprising given that Senegal has impor-
tant trade and travel links with other parts of West Africa (20,
46). It had been suggested that HIV-1 originally entered the
Senegalese population through these routes via migrant work-
ers (20). In addition, the evidence of A3 sequence in West
Brittany, France, was also initially surprising and was the first
indication of this virus in Europe. Vallet et al. (47) suggest that
the presence of non-B subtype sequences in northwest France
is likely due to either African immigrants in the region or
returning fishermen who had traveled to west African coun-
tries. Therefore, as seen in West Africa, the transmission of
HIV-1 from Africa to northwest France was not unlikely.
Understanding the genetic diversity and molecular epidemi-
ology of the various circulating viral strains is important for a
number of reasons. First of all, these studies can help us eval-
uate the patterns of disease spread and provide us with a tool
for tracking the virus. As we have shown, there is evidence of
A3 not only in various countries of West and Central Africa
but also in northwest France. Second, characterizing the epi-
demiology of the different viruses assists in studies regarding
biological characteristics of these viruses and the biologic con-
sequences of these viral interactions. Although a number of
studies have shown associations between viral genotype and
disease phenotype (12, 13, 15–19, 22, 25, 32, 39), some cross-
sectional studies have not been able to corroborate these find-
ings (1, 10, 23). Several studies have indicated a slower disease
progression for CRF02_AG or subtype A-infected individuals
relative to other non-A subtypes (17, 18, 22). Furthermore, in
a study that teased out the distinctions between subtype A
viruses, Sarr et al. (42) uncovered different levels of interaction
with HIV-2. These authors found that the in vivo interaction
between HIV-1 and HIV-2 is influenced by HIV-1 subtype and
that the prevalence of A3 viruses (previously referred to as
HIV-1 subtype A subcluster 2 viruses) was significantly higher
in dually infected individuals compared to women who were
singly infected with HIV-1 (42). This suggested that the poten-
tial protective effect of HIV-2 would be less against A3 viruses
relative to the predominant CRF02_AG. It is possible that
future studies that similarly make more accurate subtype and
sub-subtype distinctions will better clarify findings regarding
the association between viral genotype and biological pheno-
type. Finally, the further characterization of the predominant
HIV-1 subtypes, sub-subtypes, and circulating recombinant
forms in a given population will enhance our understanding of
viral diversity critical to the informed design of interventions,
therapies, and vaccines (8). Although the importance of
matching a vaccine candidate to regional circulating strains is
yet unclear, incorporation of local strains might maximize the
efficacy of a potential vaccine candidate (8).
We have characterized and described a new sub-subtype of
HIV-1 termed A3. We have found evidence of sub-subtype A3
in Senegal, as well as in other neighboring West and Central
African countries. In addition, we have identified the presence
of A3 in northwest France but note that this case is likely
traceable to West Africa. We have documented the presence
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of A3 in the Senegalese high-risk populations in the late 1980s,
with significant spread within that population to the present
time. Continued monitoring and future molecular epidemio-
logic studies will elucidate the role of HIV-1 sub-subtype A3 in
the global epidemic. It will also allow the study of viral varia-
tion and its impact on the distribution, dynamics, and conse-
quences of virus infection in humans.
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